var data={"title":"Treatment protocols for anal cancer","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for anal cancer</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-anal-cancer/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-anal-cancer/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-anal-cancer/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-anal-cancer/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-anal-cancer/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-anal-cancer/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-anal-cancer/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 16, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H801530553\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with anal cancer, both for primary treatment of locoregional disease, and for treatment of advanced disease. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with anal cancer. Additional regimens may be added over time, particularly as treatment for anal cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with anal. Clinicians should refer to the individual disease-oriented topic review that discusses the use of these protocols in appropriate clinical situations. (See <a href=\"topic.htm?path=clinical-features-staging-and-treatment-of-anal-cancer\" class=\"medical medical_review\">&quot;Clinical features, staging, and treatment of anal cancer&quot;</a>.)</p><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H801530570\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H21183931\"><span class=\"h2\">Initial therapy for locoregional disease</span></p><p class=\"headingAnchor\" id=\"H801530598\"><span class=\"h3\">Mitomycin plus fluorouracil and RT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F87178\" class=\"graphic graphic_table graphicRef87178 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H3094809953\"><span class=\"h3\">Mitomycin plus capecitabine and RT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F109549\" class=\"graphic graphic_table graphicRef109549 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H2636132120\"><span class=\"h3\">Cisplatin plus fluorouracil and RT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F87177\" class=\"graphic graphic_table graphicRef87177 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H21183923\"><span class=\"h2\">Advanced disease</span></p><p class=\"headingAnchor\" id=\"H21183950\"><span class=\"h3\">Cisplatin plus fluorouracil</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F89157\" class=\"graphic graphic_table graphicRef89157 \">table 4</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 87181 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H801530553\" id=\"outline-link-H801530553\">INTRODUCTION</a></li><li><a href=\"#H801530570\" id=\"outline-link-H801530570\">REGIMENS</a><ul><li><a href=\"#H21183931\" id=\"outline-link-H21183931\">Initial therapy for locoregional disease</a><ul><li><a href=\"#H801530598\" id=\"outline-link-H801530598\">- Mitomycin plus fluorouracil and RT</a></li><li><a href=\"#H3094809953\" id=\"outline-link-H3094809953\">- Mitomycin plus capecitabine and RT</a></li><li><a href=\"#H2636132120\" id=\"outline-link-H2636132120\">- Cisplatin plus fluorouracil and RT</a></li></ul></li><li><a href=\"#H21183923\" id=\"outline-link-H21183923\">Advanced disease</a><ul><li><a href=\"#H21183950\" id=\"outline-link-H21183950\">- Cisplatin plus fluorouracil</a></li></ul></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/87181|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/87178\" class=\"graphic graphic_table\">- Mitomycin plus FU and RT for anal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/109549\" class=\"graphic graphic_table\">- MMC and capecitabine with RT locally advanced anal carcinoma</a></li><li><a href=\"image.htm?imageKey=ONC/87177\" class=\"graphic graphic_table\">- Cisplatin plus FU with RT for anal cancer</a></li><li><a href=\"image.htm?imageKey=ONC/89157\" class=\"graphic graphic_table\">- Cisplatin and FU squamous cell cancer</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-staging-and-treatment-of-anal-cancer\" class=\"medical medical_review\">Clinical features, staging, and treatment of anal cancer</a></li></ul></div></div>","javascript":null}